Association of monocytic leukemia in patients with extreme leukocytosis

Cuttner, Janet; Conjalka, Michael S.; Reilly, Margaret C.; Goldberg, Judith D.; Reisman, Arlene; Meyer, Richard J.; Holland, James F.

doi:10.1016/0002-9343(80)90467-2

Cited by 73 publications

(31 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Given the fact that SDF‐1 is constitutively produced by stromal cells from the bone marrow and other tissues ( Tashiro et al , 1993 ; Bleul et al, 1996a ), one might speculate that it contributes to marrow and tissue infiltration of leukaemic blasts. Indeed, infiltration of non‐haematopoietic tissues such as gum or skin is most often observed in AML with monocytic differentiation (AML FAB M4 and M5) ( Cuttner et al, 1980 ), which expresses the greatest level of CXCR4 among all AML subtypes. However, quantitative data on SDF‐1 production in different tissues are missing and bone marrow infiltration is also observed in AML subtypes with low or absent expression of CXCR4.…”

Section: Discussionmentioning

confidence: 99%

Functional response of leukaemic blasts to stromal cell‐derived factor‐1 correlates with preferential expression of the chemokine receptor CXCR4 in acute myelomonocytic and lymphoblastic leukaemia

et al. 2000

View full text Add to dashboard Cite

Summary. The chemokine stromal cell-derived factor-1 (SDF-1) that is released by bone marrow (BM) stromal cells and contributes to stem cell homing may also play a role in the trafficking of leukaemic cells. We analysed SDF-1-induced intracellular calcium fluxes in leukaemic blasts from the peripheral blood of patients with newly diagnosed acute myeloid leukaemia (AML) and lymphoblastic leukaemia (B-lineage ALL), determined the effect of BM stromal cell-conditioned medium on in vitro transendothelial migration (TM) and measured expression of the SDF-1 receptor, CXCR4, by flow cytometry. AML FAB M1/2 blasts did not show calcium fluxes and TM was not stimulated. In myelomonocytic AML (M4/5), however, SDF-1 induced significant calcium fluxes and TM was increased twofold by the conditioned medium. M3 and M4 blasts with eosinophilia (M4eo) showed intermediate activity and M6 blasts showed no functional activity. In ALL, strong calcium fluxes and increased TM (2.5-fold) were observed. Accordingly, expression of CXCR4 was low in undifferentiated (M0) AML, myeloid (M1/2) AML and erythroid (M6) AML, but high [mean fluorescence (MF) . 50] in promyelocytic (M3) AML, myelomonocytic (M4/5) AML and B-lineage ALL. We conclude that, in AML, SDF-1 is preferentially active in myelomonocytic blasts as a result of differentiation-related expression of CXCR4. Functional activity of SDF-1 and high expression of CXCR4 in B-lineage ALL is in accordance with the previously described activity of SDF-1 in early B cells. SDF-1 may contribute to leukaemic marrow infiltration, as suggested by increased CXCR4 expression and migratory response in BM-derived blasts compared with circulating cells.

show abstract

Section: Discussionmentioning

confidence: 99%

Functional response of leukaemic blasts to stromal cell‐derived factor‐1 correlates with preferential expression of the chemokine receptor CXCR4 in acute myelomonocytic and lymphoblastic leukaemia

et al. 2000

View full text Add to dashboard Cite

show abstract

“…67,68 Hyperleukocytosis is present in 10% to 20% of patients with AML, and the development of leukostasis carries a grim prognosis, with 20% to 40% of patients dying within the first week of diagnosis. [69][70][71] Treatment of hyperleukocytosis or leukostasis is done via cytoreduction with either chemotherapy (remission induction therapy or hydroxyurea) or leukapheresis. The definitive treatment of hyperleukocytosis in AML patients is initiation of remission induction therapy.…”

Section: Improvements In Supportive Care For Blood Lineage Dysfunctionmentioning

confidence: 99%

How Center Volumes Affect Early Outcomes in Acute Myeloid Leukemia

Hahn

Jamy

Nunnery

et al. 2015

Clinical Lymphoma Myeloma and Leukemia

View full text Add to dashboard Cite

“…For this reason, CNS prophylaxis is not generally a feature of treatment for adult AML. CNS relapse in AML has been reported to be more common in children and in cases of AML with monocytic differentiation 34,35 . The majority of CNS relapses occur in the setting of systemic relapse 34,36 .…”

Section: Acute Myeloid Leukaemiamentioning

confidence: 99%

Central nervous system prophylaxis in haematological malignancies

Wellwood

Taylor

2002

Internal Medicine Journal

View full text Add to dashboard Cite

Given the poor prognosis of central nervous system (CNS) involvement in haematological malignancies, management is directed towards prevention. CNS prophylaxis may take the form of intrathecal therapy, cranial irradiation, systemic therapy or some combination of these. The toxicity of these methods is an important consideration. A risk-orientated approach to the delivery of CNS prophylaxis in each disorder is required.

show abstract

Association of monocytic leukemia in patients with extreme leukocytosis

Cited by 73 publications

References 15 publications

Functional response of leukaemic blasts to stromal cell‐derived factor‐1 correlates with preferential expression of the chemokine receptor CXCR4 in acute myelomonocytic and lymphoblastic leukaemia

Functional response of leukaemic blasts to stromal cell‐derived factor‐1 correlates with preferential expression of the chemokine receptor CXCR4 in acute myelomonocytic and lymphoblastic leukaemia

How Center Volumes Affect Early Outcomes in Acute Myeloid Leukemia

Central nervous system prophylaxis in haematological malignancies

Contact Info

Product

Resources

About